Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 127Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
DRUG DEVELOPMENT
Year : 2010  |  Volume : 1  |  Issue : 4  |  Page : 146-150

Personalized medicine: Striding from genes to medicines


Cardiff Research Consortium (Knowledge Services), Capita India, India

Correspondence Address:
Sunita R Nair
Deputy General Manager, Cardiff Research Consortium (Knowledge Services), Capita India, 5th Floor, Tower 1, Logitech Park, Saki Naka, Andheri (East), Mumbai - 400 072
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.71775

Rights and Permissions

Personalized medicine has the potential of revolutionizing patient care. This treatment modality prescribes therapies specific to individual patients based on pharmacogenetic and pharmacogenomic information. The mapping of the human genome has been an important milestone in understanding the interindividual differences in response to therapy. These differences are attributed to genotypic differences, with consequent phenotypic expression. It is important to note that targeted therapies should ideally be accompanied by a diagnostic marker. However, most efforts are being directed toward developing both these separately; the former by pharmaceutical companies and the later by diagnostic companies. Further, this companion strategy will be successful only when the biomarkers assayed are differentiated on a value-based approach rather than a cost-based approach, especially in countries that reimburse disease management costs. The advantages of using personalized therapies are manifold: targeted patient population; avoidance of drug-related toxicities and optimization of costs in nonresponder patients; reduction in drug development costs, and fewer patients to be tested in clinical trials. The success of personalized therapy in future will depend on a better understanding of pharmacogenomics and the extension of these scientific advances to all countries.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3135    
    Printed207    
    Emailed1    
    PDF Downloaded705    
    Comments [Add]    
    Cited by others 9    

Recommend this journal